EGFR-Tyrosine Kinase Inhibitor (EGFR-TKI) for Non-Small Cell Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 October 2026 | Viewed by 1416
Special Issue Editor
Interests: EMT; targeted therapy resistance; extracellular vesicles; liquid biopsy; lung cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
EGFR-bearing activation mutations represent a key oncogene-driver of non-small cell lung cancer (NSCLC). The identification of structural changes induced by such mutations in the kinase domain of receptor promoted the rational development of targeted tyrosine kinase inhibitors (TKIs). Although great clinical benefits were obtained with EGFR TKIs through appropriate patient stratification, the continuous and selective drug pressure determined in tumors, a growing number of adaptation mechanisms and acquired resistance emerged, representing challenges in the prevention of cancer progression. New targeted agents and combined strategies need to be developed to overcome resistance to EGFR TKIs.
This Special Issue invites original research and comprehensive reviews on “EGFR-Tyrosine Kinase Inhibitor (EGFR-TKI) for Non-Small Cell Lung Cancer”. By integrating recent advances, this Special Issue aims to offer a comprehensive perspective on novel therapeutic approaches in EGFR-TKI treatment for NSCLC.
Dr. Francesca Iommelli
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- EGFR TKIs
- secondary mutations
- alternative signaling pathway activation cancer progression
- lung cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
